biote Corp. (NASDAQ:BTMD) CFO Sells $86,116.32 in Stock

biote Corp. (NASDAQ:BTMD) CFO Robert Charles Peterson sold 11,376 shares of the stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $7.57, for a total transaction of $86,116.32. Following the transaction, the chief financial officer now directly owns 32,874 shares in the company, valued at approximately $248,856.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

biote Stock Performance

Shares of BTMD stock opened at $8.00 on Friday. biote Corp. has a one year low of $3.65 and a one year high of $8.22. The company’s 50-day simple moving average is $6.65 and its 200-day simple moving average is $5.70. The stock has a market capitalization of $496.32 million, a price-to-earnings ratio of 72.73 and a beta of 0.98.

biote (NASDAQ:BTMD) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.05 by $0.18. biote had a net margin of 4.30% and a negative return on equity of 36.67%. The business had revenue of $46.80 million for the quarter, compared to analysts’ expectations of $47.09 million. As a group, research analysts forecast that biote Corp. will post 0.56 EPS for the current year.

Hedge Funds Weigh In On biote

Several large investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new stake in biote during the fourth quarter worth about $53,000. Bailard Inc. acquired a new stake in biote during the fourth quarter worth about $96,000. SW Investment Management LLC raised its stake in biote by 3.5% during the fourth quarter. SW Investment Management LLC now owns 675,000 shares of the company’s stock worth $3,334,000 after acquiring an additional 22,651 shares during the period. Finally, Bandera Partners LLC raised its stake in biote by 7.5% during the fourth quarter. Bandera Partners LLC now owns 1,832,732 shares of the company’s stock worth $9,054,000 after acquiring an additional 127,410 shares during the period. Institutional investors own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.